Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Sees Large Increase in Short Interest

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 43,100 shares, an increase of 498.6% from the February 13th total of 7,200 shares. Based on an average trading volume of 196,400 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.0% of the company's shares are sold short.

Chugai Pharmaceutical Stock Up 0.8 %

CHGCY stock traded up $0.19 during trading on Friday, hitting $23.40. 144,432 shares of the company's stock traded hands, compared to its average volume of 200,494. The firm has a market capitalization of $77.01 billion, a P/E ratio of 30.39 and a beta of 0.77. The business has a fifty day simple moving average of $22.82 and a two-hundred day simple moving average of $22.97. Chugai Pharmaceutical has a 1 year low of $14.52 and a 1 year high of $27.19.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.18 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a return on equity of 21.53%. On average, equities research analysts predict that Chugai Pharmaceutical will post 0.74 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.